| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A call for advocacy and patient voice to eliminate hepatitis B virus infection
|
Matthews, Philippa C
|
|
|
7 |
4 |
p. 282-285
|
artikel
|
| 2 |
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial
|
Solomon, Sunil S
|
|
|
7 |
4 |
p. 307-317
|
artikel
|
| 3 |
Correction to Lancet Gastroenterol Hepatol 2022; 7: 17–27
|
|
|
|
7 |
4 |
p. e8
|
artikel
|
| 4 |
Correction to Lancet Gastroenterol Hepatol 2022; 7: 294–306
|
|
|
|
7 |
4 |
p. e8
|
artikel
|
| 5 |
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study
|
Alexander, James L
|
|
|
7 |
4 |
p. 342-352
|
artikel
|
| 6 |
Dangerous Medicine
|
Burki, Talha
|
|
|
7 |
4 |
p. 292
|
artikel
|
| 7 |
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
|
Mantovani, Alessandro
|
|
|
7 |
4 |
p. 367-378
|
artikel
|
| 8 |
Endoscopic interventions for stricturing Crohn's disease
|
Goren, Idan
|
|
|
7 |
4 |
p. 279-280
|
artikel
|
| 9 |
Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial
|
Schulberg, Julien D
|
|
|
7 |
4 |
p. 318-331
|
artikel
|
| 10 |
Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?
|
Chhibba, Tarun
|
|
|
7 |
4 |
p. 280-282
|
artikel
|
| 11 |
Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO
|
Artenie, Adelina
|
|
|
7 |
4 |
p. 353-366
|
artikel
|
| 12 |
Navigating the unknowns of idiopathic pancreatitis
|
Crichton, Eleanor
|
|
|
7 |
4 |
p. 293
|
artikel
|
| 13 |
Oral faecal microbiota transplantation in ulcerative colitis
|
Yuan, Tan Yi
|
|
|
7 |
4 |
p. 286
|
artikel
|
| 14 |
Oral faecal microbiota transplantation in ulcerative colitis – Authors' reply
|
Haifer, Craig
|
|
|
7 |
4 |
p. 286-287
|
artikel
|
| 15 |
Ranking treatments in the network meta-analysis should consider the certainty of evidence
|
Li, Meixuan
|
|
|
7 |
4 |
p. 287-288
|
artikel
|
| 16 |
Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply
|
Lasa, Juan S
|
|
|
7 |
4 |
p. 288
|
artikel
|
| 17 |
Research in Brief
|
Baker, Holly
|
|
|
7 |
4 |
p. 291
|
artikel
|
| 18 |
Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial
|
Loras, Carme
|
|
|
7 |
4 |
p. 332-341
|
artikel
|
| 19 |
Shining a light on international alcohol industry lobbying
|
The Lancet Gastroenterology & Hepatology,
|
|
|
7 |
4 |
p. 275
|
artikel
|
| 20 |
Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations
|
Klein, Marina B
|
|
|
7 |
4 |
p. 277-279
|
artikel
|
| 21 |
17th Congress of ECCO
|
Brierley, Rob
|
|
|
7 |
4 |
p. 290
|
artikel
|
| 22 |
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
|
Danese, Silvio
|
|
|
7 |
4 |
p. 294-306
|
artikel
|
| 23 |
Treat to target with ustekinumab for Crohn's disease
|
Ungaro, Ryan C
|
|
|
7 |
4 |
p. 276-277
|
artikel
|
| 24 |
Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada
|
Kuenzig, M Ellen
|
|
|
7 |
4 |
p. 288-289
|
artikel
|
Tijdschrift beschrijving